Burning Rock Biotech (BNR) Return on Sales (2019 - 2026)

Burning Rock Biotech's Return on Sales history runs 8 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), while the FY2025 annual figure was 0.0%, up 1.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.0% in Q2 2025, with the low at 0.02% in Q2 2022.
• The 5-year median for Return on Sales is 0.01% (2023), against an average of 0.01%.
• The sharpest annual moves came in 2022 and 2023: Return on Sales changed 0 bps in 2022, then rose 1 bps in 2023.
• Burning Rock Biotech's Return on Sales stood at 0.02% in 2022, then increased by 12 bps to 0.01% in 2023, then soared by 58 bps to 0.01% in 2024, then soared by 81 bps to 0.0% in 2025, then slumped by 46 bps to 0.0% in 2026.
• Business Quant data shows BNR's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.